Eromona Whiskey, Christian Bachmann, Olubanke Dzahini, David Taylor, Ebenezer Oloyede
{"title":"难治性精神分裂症黑人患者氯氮平的悖论","authors":"Eromona Whiskey, Christian Bachmann, Olubanke Dzahini, David Taylor, Ebenezer Oloyede","doi":"10.1038/s44220-025-00411-9","DOIUrl":null,"url":null,"abstract":"Clozapine is currently the only licensed medication for treatment-resistant schizophrenia (TRS). Ethnic inequalities in treatment with clozapine have been described extensively, particularly regarding the effect on Black ethnic groups. Here we explore the reasons for clozapine underuse in this population, identifying potential misconceptions and providing suggestions to address these barriers. Whiskey et al. discuss the reasons for the underuse of clozapine among Black individuals with treatment-resistant schizophrenia and propose changes to enhance clinicians’ confidence in prescribing it to this population.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 4","pages":"402-407"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The paradox of clozapine in Black people with treatment-resistant schizophrenia\",\"authors\":\"Eromona Whiskey, Christian Bachmann, Olubanke Dzahini, David Taylor, Ebenezer Oloyede\",\"doi\":\"10.1038/s44220-025-00411-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clozapine is currently the only licensed medication for treatment-resistant schizophrenia (TRS). Ethnic inequalities in treatment with clozapine have been described extensively, particularly regarding the effect on Black ethnic groups. Here we explore the reasons for clozapine underuse in this population, identifying potential misconceptions and providing suggestions to address these barriers. Whiskey et al. discuss the reasons for the underuse of clozapine among Black individuals with treatment-resistant schizophrenia and propose changes to enhance clinicians’ confidence in prescribing it to this population.\",\"PeriodicalId\":74247,\"journal\":{\"name\":\"Nature mental health\",\"volume\":\"3 4\",\"pages\":\"402-407\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature mental health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44220-025-00411-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature mental health","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44220-025-00411-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The paradox of clozapine in Black people with treatment-resistant schizophrenia
Clozapine is currently the only licensed medication for treatment-resistant schizophrenia (TRS). Ethnic inequalities in treatment with clozapine have been described extensively, particularly regarding the effect on Black ethnic groups. Here we explore the reasons for clozapine underuse in this population, identifying potential misconceptions and providing suggestions to address these barriers. Whiskey et al. discuss the reasons for the underuse of clozapine among Black individuals with treatment-resistant schizophrenia and propose changes to enhance clinicians’ confidence in prescribing it to this population.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
